Dr Joseph Paul Desimone, MD | |
1 Medical Center Dr, Dhmc Cardiac Surgery, Lebanon, NH 03756-1000 | |
(603) 650-6050 | |
Not Available |
Full Name | Dr Joseph Paul Desimone |
---|---|
Gender | Male |
Speciality | Cardiac Surgery |
Experience | 27 Years |
Location | 1 Medical Center Dr, Lebanon, New Hampshire |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1528118643 | NPI | - | NPPES |
1013963 | Medicaid | VT | |
30207015 | Medicaid | NH |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208G00000X | Thoracic Surgery (cardiothoracic Vascular Surgery) | 11128 (New Hampshire) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Central Vermont Home Health & Hospice | Barre, VT | Home health agency |
Mary Hitchcock Memorial Hospital | Lebanon, NH | Hospital |
Cheshire Medical Center | Keene, NH | Hospital |
Cottage Hospital | Woodsville, NH | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Dartmouth-hitchcock Clinic | 4183537509 | 1139 |
Mary Hitchcock Memorial Hospital | 4486561164 | 964 |
News Archive
Since mid-January, the Translational Genomics Research Institute has joined the world-wide effort to test for the SARS-CoV-2 virus causing the COVID-19 disease.
Cancer Research UK scientists have found that having a cancer false alarm could put people off checking out cancer symptoms they develop in the future.
Durata Therapeutics today announced the Company has attained worldwide rights for the development and commercialization of Durata's lead product, dalbavancin, a long-acting, intravenous (IV) lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections (abSSSI). In December 2010, Durata acquired from RaQualia Pharma commercialization rights for dalbavancin in Japan.
A new oral medication known as IMC-1, developed by Innovative Med Concepts, proved highly effective at reducing pain and other symptoms of fibromyalgia (FM) in patients in a recent clinical trial.
› Verified 9 days ago
Entity Name | Mary Hitchcock Memorial Hospital |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1023092053 PECOS PAC ID: 4486561164 Enrollment ID: O20031126000258 |
News Archive
Since mid-January, the Translational Genomics Research Institute has joined the world-wide effort to test for the SARS-CoV-2 virus causing the COVID-19 disease.
Cancer Research UK scientists have found that having a cancer false alarm could put people off checking out cancer symptoms they develop in the future.
Durata Therapeutics today announced the Company has attained worldwide rights for the development and commercialization of Durata's lead product, dalbavancin, a long-acting, intravenous (IV) lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections (abSSSI). In December 2010, Durata acquired from RaQualia Pharma commercialization rights for dalbavancin in Japan.
A new oral medication known as IMC-1, developed by Innovative Med Concepts, proved highly effective at reducing pain and other symptoms of fibromyalgia (FM) in patients in a recent clinical trial.
› Verified 9 days ago
Entity Name | Dartmouth-hitchcock Clinic |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1548210198 PECOS PAC ID: 4183537509 Enrollment ID: O20040809000442 |
News Archive
Since mid-January, the Translational Genomics Research Institute has joined the world-wide effort to test for the SARS-CoV-2 virus causing the COVID-19 disease.
Cancer Research UK scientists have found that having a cancer false alarm could put people off checking out cancer symptoms they develop in the future.
Durata Therapeutics today announced the Company has attained worldwide rights for the development and commercialization of Durata's lead product, dalbavancin, a long-acting, intravenous (IV) lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections (abSSSI). In December 2010, Durata acquired from RaQualia Pharma commercialization rights for dalbavancin in Japan.
A new oral medication known as IMC-1, developed by Innovative Med Concepts, proved highly effective at reducing pain and other symptoms of fibromyalgia (FM) in patients in a recent clinical trial.
› Verified 9 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Joseph Paul Desimone, MD 1 Medical Center Dr, Dhmc Cardiac Surgery, Lebanon, NH 03756-1000 Ph: (603) 650-6050 | Dr Joseph Paul Desimone, MD 1 Medical Center Dr, Dhmc Cardiac Surgery, Lebanon, NH 03756-1000 Ph: (603) 650-6050 |
News Archive
Since mid-January, the Translational Genomics Research Institute has joined the world-wide effort to test for the SARS-CoV-2 virus causing the COVID-19 disease.
Cancer Research UK scientists have found that having a cancer false alarm could put people off checking out cancer symptoms they develop in the future.
Durata Therapeutics today announced the Company has attained worldwide rights for the development and commercialization of Durata's lead product, dalbavancin, a long-acting, intravenous (IV) lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections (abSSSI). In December 2010, Durata acquired from RaQualia Pharma commercialization rights for dalbavancin in Japan.
A new oral medication known as IMC-1, developed by Innovative Med Concepts, proved highly effective at reducing pain and other symptoms of fibromyalgia (FM) in patients in a recent clinical trial.
› Verified 9 days ago
Anthony W Discipio, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-7390 | |
John H Sanders Jr., M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Not Enrolled in Medicare Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-7390 | |
Dr. Bryan Payne Stanifer, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Dhmc Department Of Surgery, Lebanon, NH 03756 Phone: 603-650-8022 | |
Joseph David Phillips, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Dartmouth Hitchcock - Thoracic Surgery, Lebanon, NH 03756 Phone: 603-650-2068 | |
Lawrence Joseph Dacey, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Medicare Enrolled Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-7390 | |
Dr. Jock N Mccullough, MD Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Dhmc - Cardiac Surgery, Lebanon, NH 03756 Phone: 603-650-7390 Fax: 603-650-6346 |